Arcataur Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Arcataur Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$636K	Buy	1,020 +12	+1%	+$8.17K	0.16%	58
2026 Q1	$779K	Hold	1,008	–	–	0.22%	46
2025 Q4	$778K	Hold	1,008	–	–	0.22%	47
2025 Q3	$567K	Sell	1,008 -30	-3%	-$17K	0.17%	55
2025 Q2	$545K	Buy	1,038 +37	+4%	+$20.7K	0.17%	57
2025 Q1	$635K	Sell	1,001 -52	-5%	-$35.8K	0.22%	45
2024 Q4	$750K	Buy	1,053 +267	+34%	+$224K	0.25%	41
2024 Q3	$826K	Sell	786 -10	-1%	-$11.1K	0.28%	39
2024 Q2	$837K	Sell	796 -4	-0.5%	-$3.88K	0.3%	37
2024 Q1	$770K	Hold	800	–	–	0.28%	38
2023 Q4	$703K	Hold	800	–	–	0.27%	36
2023 Q3	$658K	Hold	800	–	–	0.28%	36
2023 Q2	$575K	Buy	+800	New	+$617K	0.24%	41

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arcataur Capital Management's REGN Position: Q2 2026 in Review

Arcataur Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 1.2% in Q2 2026, buying an estimated $8.17K and bringing the position to 1,020 shares worth $636K. The position accounts for 0.16% of the portfolio, ranked #58.

Arcataur Capital Management first reported a position in REGN in Q2 2023 and has held it in 13 quarters since. The position peaked at $837K in Q2 2024. 955 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Arcataur Capital Management held 1,020 shares of Regeneron Pharmaceuticals worth $636K as of Q2 2026.
Arcataur Capital Management bought 12 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.17K.
Regeneron Pharmaceuticals made up 0.16% of Arcataur Capital Management's portfolio in Q2 2026, its #58 holding.
Arcataur Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Arcataur Capital Management's Regeneron Pharmaceuticals position peaked at $837K in Q2 2024.
955 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Arcataur Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.